Weekly gemcitabine as a radiosensitiser fore the treatment of brain metastases in patiens with non-small cell lung cancer: Phase I trial

Chinese Medical Journal

Volumn 120, Issue 6, 2007, Pages 458-462

  Huang, Yu Juan ^a   Wu, Yi Long ^a   Xie, Song Xi ^a   Yang, Jing Ji ^a   Huang, Yi Sheng ^a   Liao, Ri Qiang ^a  

^a GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

Brain metastases; Gemcitabine; Phase I study; Radiosensitisation

Indexed keywords

DEXAMETHASONE; GEMCITABINE; MANNITOL; RADIOSENSITIZING AGENT;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; BRAIN METASTASIS; BRAIN RADIATION; CANCER PATIENT; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; HUMAN; KARNOFSKY PERFORMANCE STATUS; LUNG NON SMALL CELL CANCER; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; NEUROTOXICITY; NEUTROPENIA; PATIENT SELECTION; PHASE 1 CLINICAL TRIAL; RADIATION DOSE; SEIZURE; THROMBOCYTOPENIA;

EID: 34047101351     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00029330-200703020-00004     Document Type: Article

References (26)

1. Wen PY, McLaren Black P, Loeffler JS. Metastatic brain cancer. In: De Vita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: principles and practice of oncology. 6th ed. Philadelphia: Lippincott Williams and Wilkins; 1999: 2655-2670.
2. Ceresoli GL, Reni M, Chiesa G, Carretta A, Schipani S, Passoni P, et al. Brain metastases in locally advanced non-small cell lung cancer after multimodality treatment: risk factors analysis. Cancer 2002; 95: 605-612.
3. Lagerwaard FJ, Levendag PC, Nowak PJ, Eijkenboom WM, Hanssens PE, Schmitz PI. Identification of prognostic factors in patients with brain metastases: a review of 1292 patients. Int J Radiat Oncol Biol Phys 1999; 43: 795-803.
4. Shahidi H, Kvale PA. Long-term survival following surgical treatment of solitary brain metastasis in non-small cell lung cancer. Chest 1996; 109: 271-276.
5. van Vulpen M, Kal HB, Taphoorn MJ, El-Sharouni SY. Changes in blood-brain barrier permeability induced by radiotherapy: implications for timing of chemotherapy? Oncol Rep 2002; 9: 683-688.
6. Crinò L, Scagliotti GV, Ricci S, De Marinis F, Rinaldi M, Gridelli C, et al. Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small cell lung cancer: a randomized phase III study of the Italian Lung Cancer Project. J Clin Oncol 1999; 17: 3522-3530.
7. Moscetti L, Nelli F, Felici A, Rinaldi M, De Santis S, D'Auria G, et al. Up-front chemotherapy and radiation treatment in newly diagnosed nonsmall cell lung cancer with brain metastases: survey by Outcome Research Network for Evaluation of Treatment Results in Oncology. Cancer 2006;109: 274-281.
8. Kim DY, Lee KW, Yun T, Kim DW, Kim TY, Dae SH, et al. Efficacy of platinum-based chemotherapy after cranial radiation in patients with brain metastasis from non-small cell lung cancer. Oncol Rep 2005; 14: 207-211.
9. Folstein MF, Folstein SE, Mchugh PR. "Mini-mental state." A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198.
10. Davis JR, Fernandes C, Zalcberg JR. Gemcitabine and the blood brain barrier. Aust NZ J Med 1999; 29: 831-832.
11. Shipley LA, Brown TJ, Cornpropst JD, Hamilton M, Daniels WD, Culp HW. Metabolism and disposition of gemcitabine, an oncolytic deoxycytidine analog, in mice, rats, and dogs. Drug Metab Dispos 1992; 20: 849-855.
12. Emerich DF, Dean RL, Marsh J, Pink M, Lafreniere D, Snodgrass P, et al. Intravenous Cereport (RMP-7) enhances delivery of hydrophilic chemotherapeutics and increases survival in rats with metastatic tumors in the brain. Pharm Res 2000; 17: 1212-1219.
13. Gridelli C, Perrone F, Gallo C, Rossi A, Barletta E, Barzelloni ML, et al. Single agent gemcitabine as a second line treatment in patients with advanced non small cell lung cancer (NSCLC): a phase II trail. Anticancer Res 1999; 19: 4535-4538.
14. Maraveyas A, Sgouros J, Upadhyay S, Abdel-Hamid AH, Holmes M, Lind M. Gemcitabine twice weekly as a radiosensitiser for the treatment of brain metastases in patients with carcinoma: a phase I study. Brit J Cancer 2005; 92: 815-819.
15. Carmichael J. The role of gemcitabine in the treatment of other tumours. Br J Cancer 1998; 78 Suppl 3: s21-s25.
16. McGinn CJ, Lawrence TS. Recent advances in the use of radiosensitizing nucleosides. Semin Radiat Oncol 2001; 11: 270-280.
17. Lawrence TS, Blackstock AW, McGinn C. The mechanism of action of radiosensitization of conventional chemotherapeutic agents. Semin Radiat Oncol 2003; 13: 13-21.
18. Lawrence TS, Davis MA, Hough A, Rehemtulla A. The role of apoptosis in 20, 20-difluoro-20-deoxycytidine (gemcitabine)-mediated radiosensitization. Clin Cancer Res 2001; 7: 314-319.
19. Milas L, Fujii T,Hunter N, Elshaikh M, Mason K, Plunkett W, et al. Enhancement of tumor radioresponse in vivo by gemcitabine. Cancer Res 1999; 59: 107-114.
20. Lawrence TS, Chang EY, Hahn TM, Hertel LW, Shewach DS. Radiosensitization of pancreatic cancer cells by 2′,2′-difluoro- 2′-deoxycytidine. Int J Radiat Oncol Biol Phys 1996; 34: 867-872.
21. Shewach DS, Hahn TM, Chang E, Hertel LW, Lawrence TS. Metabolism of 2′,2′-difluoro-2′-deoxycytidine and radiation sensitization of human colon carcinoma cells. Cancer Res 1994; 54: 3218-3223.
22. Shewach DS. Radiosensitization of human tumor cells by gemcitabine in vitro. Semin Oncol 1995; 22: 68-71.
23. Egorin MJ, Zuhowski EG, McCully CM, Blaney SM, Kerr JZ, Berg SL, et al. Pharmacokinetics of intrathecal gemcitabine in nonhuman primates. Clin Cancer Res 2002; 8: 2437-2442.
24. New P. Radiation injury to the nervous system. Curr Opin Neurol 2001; 14: 725-734.
25. Sheline GE. Therapuetic irradiation and brain injury. Int J Radiat Oncol Biol Phys 1980; 6: 1215-1228.
26. Valk PE, Dillon WP. Radiation injury of the brain. AJNR Am J Neuroradiol 1991; 12: 45-62.